Sigma-1 receptor and seizures

Simple item page
dc.contributor.authorVavers, Edijs
dc.contributor.authorZvejniece, Liga
dc.contributor.authorDambrova, Maija
dc.contributor.institutionFaculty of Pharmacy
dc.date.accessioned2023-05-02T11:25:02Z
dc.date.available2023-05-02T11:25:02Z
dc.date.issued2023-05
dc.descriptionFunding Information: This review article was supported by the European Regional Development Fund Project No. 1.1.1.2/VIAA/2/18/376 "Sigma chaperone protein as a novel drug target". Authors were supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 857394 . EV would like to thank Jolanta Jonane for helping with the tables and references. Funding Information: This review article was supported by the European Regional Development Fund Project No. 1.1.1.2/VIAA/2/18/376 "Sigma chaperone protein as a novel drug target". Authors were supported by the European Union's Horizon 2020 research and innovation programme under grant agreement No. 857394. EV would like to thank Jolanta Jonane for helping with the tables and references. Publisher Copyright: © 2023 The Authors
dc.description.abstractOver the last decade, sigma-1 receptor (Sig1R) has been recognized as a valid target for the treatment of seizure disorders and seizure-related comorbidities. Clinical trials with Sig1R ligands are underway testing therapies for the treatment of drug-resistant seizures, developmental and epileptic encephalopathies, and photosensitive epilepsy. However, the direct molecular mechanism by which Sig1R modulates seizures and the balance between excitatory and inhibitory pathways has not been fully elucidated. This review article aims to summarize existing knowledge of Sig1R and its involvement in seizures by focusing on the evidence obtained from Sig1R knockout animals and the anti-seizure effects of Sig1R ligands. In addition, this review article includes a discussion of the advantages and disadvantages of the use of existing compounds and describes the challenges and future perspectives on the use of Sig1R as a target for the treatment of seizure disorders.en
dc.description.statusPeer reviewed
dc.format.extent2200928
dc.identifier.citationVavers, E, Zvejniece, L & Dambrova, M 2023, 'Sigma-1 receptor and seizures', Pharmacological Research, vol. 191, 106771. https://doi.org/10.1016/j.phrs.2023.106771
dc.identifier.doi10.1016/j.phrs.2023.106771
dc.identifier.issn1043-6618
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/11859
dc.identifier.urlhttps://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/MEDLINE:37068533
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85152907541&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofPharmacological Research
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subject3.1 Basic medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.titleSigma-1 receptor and seizuresen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/systematicreview

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Sigma_1_receptor_and_seizures.pdf
Size:
2.1 MB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure